Abstract: Objective To investigate the effect of Anduolin capsule on myelosuppression in patients with esophageal cancer during radiotherapy. Methods 96 patients with esophageal cancer were treated with radiotherapy alone in the first affiliated Hospital of Xinjiang Medical University, the radiation dose was 50~60 Gy, among them, 46 patients took Anduolin capsule 4 capsules per time, 3 times a day, continuously until the end of radiotherapy, and the other 50 patients did not take any drugs during radiotherapy. The blood routine was every 5 days, and the changes of hemogram of the patients were observed. The level of leukocyte, hemoglobin and platelet were used to monitor the myelosuppression during radiotherapy. Results Among the 96 patients, there were 68 cases of male and 28 cases of male and female. Most of the lesions were located in the middle part of the chest, accounting for 50.0%, and the PS scores of the patients were all 1, of which the Han nationality was the most, accounting for 46.9%, followed by the Kazakh nationality (32.3%), while patients with stage Ⅰ, Ⅱ, Ⅲ and Ⅳ accounted for 2.1%, 5.2%, 59.4% and 33.3%, respectively. Most of the patients who took Anduolin capsule during radiotherapy had first-degree myelosuppression, while those who did not use any drugs mostly had second-degree myelosuppression. The white blood cell count of the patients treated with Anduolin capsule was (4.02 ±1.67) ×10⁹/L, while that of the unused group was (3.23 ±1.34) ×10⁹/L, and the level of platelet count was (150.26±84.46) ×10⁹/L in the use group, and(108.70±58.56) ×10⁹/L in the non-use group. Conclusion The use of Anduolin could reduce the reaction of myelosuppression in patients with esophageal cancer treated with radiotherapy alone, especially at the level of white blood cell count.

Key words: anduolin, esophageal cancer, radiotherapy alone, hemogram, myelosuppression